AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19922681
Drug: Combination reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination reverse transcriptase inhibitors
Trial: 17257428
Drug: Urodilatin (URO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urodilatin (URO) infusion for 90 minutes
Trial: 11869325
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) injection (80 units in five cases, 60 units in two cases) into four quadrants of lower esophageal sphincter (LES)
Trial: 11869325
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (BT and pneumatic dilatation)
Trial: 9272237
Drug: Levosimendan 1
RxNorm normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 1 mg intravenously
Trial: 9272237
Drug: Ethanol 0.8
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.8 g/kg alone
Trial: 1169822
Drug: Intravenous dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextran 40
Trial: 1598096
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin
Trial: 24052987
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg/day for at least 6 months)
Trial: 25665208
Drug: Combined dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dose of 5 mg x kg(‐1) of body weight of caffeine and 200 mg of Panax ginseng
Trial: 19909587
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (letrozole, 5 mg/day) + rFSH (450 IU/day)
Trial: 15564955
Drug: Haloperidol 0.5-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.5-4 mg
Trial: 18420852
Drug: Haloperidol 1
RxNorm normalized name: haloperidol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1 mg
Trial: 10673291
Drug: Quadruple antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple antibiotic therapy for one day
Trial: 10673291
Drug: Quadruple antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple antibiotic therapy for two days
Trial: 9300248
Drug: High 2-h
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High 2-h plasma NEFA and low 2-h plasma insulin concentrations in IGT subjects
Trial: 9300248
Drug: 2-h plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h plasma insulin concentration in subjects with IGT who deteriorated
Trial: 8449086
Drug: Heparin 4
RxNorm normalized name: heparin 40000 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 4 U/ml
Trial: 3518910
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate 200 mg intramuscularly weekly for 4 weeks
Trial: 23601186
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (Control)
Trial: 24635110
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with RT and concurrent chemotherapy
Trial: 22017192
Drug: Duloxetine 60/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60/120 mg/day
Trial: 20546509
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day (for previously placebo-treated patients)
Trial: 15809017
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g oral arginine
Trial: 15809017
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g oral arginine
Trial: 15809017
Drug: 13 g
RxNorm normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 g oral arginine
Trial: 11977435
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy for insomnia
Trial: 10084473
Drug: Salmeterol, 42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 42 microg, twice daily
Trial: 2257960
Drug: Serratia peptidase
RxNorm normalized name: Serratia marcescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratia peptidase (two tablets three times a day for 7-8 days)
Trial: 2257960
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets three times a day for 7-8 days)
Trial: 366145
Drug: Levamisole treatment
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole treatment
Trial: 30819262
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (38 µg or 1500 IU daily) with iron-fortified breakfast cereal
Trial: 28535235
Drug: Cephalexin plus
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin plus trimethoprim‐sulfamethoxazole (500 mg 4 times daily, plus 320 mg/1600 mg twice daily for 7 days)
Trial: 28535235
Drug: Cephalexin alone
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin alone (500 mg 4 times daily for 7 days)
Trial: 25812064
Drug: New Zealand
RxNorm normalized name: NEW ZEALAND GREEN MUSSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Zealand blackcurrant extract (300 mg·day‐1 CurraNZ; containing 105 mg anthocyanin)
Trial: 23844168
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral levodopa
Trial: 18604074
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg/kg mixed in paracetamol syrup
Trial: 15464773
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg/day, n=20)
Trial: 15464773
Drug: CPA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA plus EE2 (CPA 25 mg/day on days 5-14 plus EE2 20 microg/day on days 5-25, n=20)
Trial: 9721345
Drug: Fibrinolysis (FB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolysis (FB) treatment in AMI patients
Trial: 9721345
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in AMI patients (without FB)
Trial: 8040676
Drug: Salvage therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapies (chemotherapy, hormonal therapy, combination of cytotoxic and hormonal therapies)
Trial: 8040676
Drug: Second-line hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-line hormonal therapy
Trial: 8040676
Drug: First salvage
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First salvage therapy
Trial: 4161578
Drug: Isoniazid (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (average 6.9 mg/kg) plus thioacetazone (average 3.4 mg/kg), daily in one dose
Trial: 4161578
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of isoniazid (average 4.5 mg/kg body-weight) plus sodium PAS (average 0.22 g/kg), daily in two divided doses
Trial: 4161578
Drug: 2-phase regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-phase regimen of isoniazid (average 5.5 mg/kg) plus sodium PAS (average 0.17 g/kg), daily in one dose for 6 months, followed by isoniazid alone (average 6.8 mg/kg), daily in one dose for the second 6 months
Trial: 28074392
Drug: Cerebrolysin (CBL)
RxNorm normalized name: OH-Cbl
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (CBL) administered intramuscularly as a single daily dose of 0.1 cc/kg for 10 days, then continued weekly for 4 months.
Trial: 28074392
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard rehabilitation therapy without CBL.
Trial: 25971261
Drug: Ribavirin (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (dosing simulations)
Trial: 24011102
Drug: Teens and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teens and Toddlers intervention (18-20 weekly sessions in pre-school nurseries)
Trial: 12792150
Drug: Mesterolone 100
RxNorm normalized name: mesterolone
DrugBank: Mesterolone (DB13587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesterolone 100 mg p.o. daily
Trial: 12792150
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 160 mg p.o. daily
Trial: 12792150
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 250 mg i.m. every 21 days
Trial: 12792150
Drug: Crystalline testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalline testosterone 1,200 mg subcutaneous implantation
Trial: 10383596
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg twice daily for 8 weeks
Trial: 8707338
Drug: CAMPATH‐1H (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH‐1H (humanized antibody against the CD52 antigen)
Trial: 31340801
Drug: Intravesical gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical gemcitabine monotherapy
Trial: 24938580
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily for 8 weeks
Trial: 20845204
Drug: Embodied Conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embodied Conversational Agents (ECA) for automated health communication interventions
Trial: 11411817
Drug: Paroxetine (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-50 mg/day)
Trial: 18095197
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg gabapentin
Trial: 24190578
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg gabapentin
Trial: 20565316
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of topical amphotericin B (0.5 mg/mL) eye drops with subconjunctival injection of fluconazole (2 mg/mL)
Trial: 20565316
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin B (0.5 mg/mL) eye drops alone
Trial: 19029209
Drug: Biological assignment
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological assignment trials
Trial: 10696421
Drug: Self-supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-supervised treatment (SS)
Trial: 10696421
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Treatment (DOT) at district and provincial hospitals
Trial: 10696421
Drug: Self-supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-supervised treatment (SS) at district and provincial hospitals
Trial: 10696421
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Treatment (DOT) at referral centres
Trial: 10696421
Drug: Self-supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-supervised treatment (SS) at referral centres
Trial: 8572663
Drug: Deprenyl 10
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 10 mg/day (open label)
Trial: 9159313
Drug: Povidone-iodine ointment
RxNorm normalized name: Povidone-Iodine Ointment
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine ointment
Trial: 6195241
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no povidone-iodine ointment)
Trial: 29764260
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical fatigue and mental stress
Trial: 27577509
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 80 kVp tube voltage, 270 mg iodine (I)/mL contrast agent (Visipaque, GE Healthcare)
Trial: 27577509
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 100 kVp tube voltage, 370 mg I/mL contrast agent (Iopamiro, Bracco)
Trial: 24574444
Drug: Gabapentin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1200 mg before surgery, followed by 600 mg on day 1, 900 mg on day 2, and 1200 mg on days 3-5)
Trial: 17996818
Drug: Automated, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, daily symptom and self-reported weight monitoring intervention
Trial: 177803
Drug: 0.15 g
RxNorm normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 g phenformin
Trial: 177803
Drug: 2.55 g
RxNorm normalized name: citrate phosphate dextros soln 299 mg-2.63 gram-222 mg-2.55 gram/100 mL MISCELL SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.55 g metformin
Trial: 177803
Drug: 0.30 g
RxNorm normalized name: Titanium Dioxide 0.30 g in 3.5 g TOPICAL POWDER [3CE TRIPLE SHADOW LEMME SEE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 g buformin
Trial: 177803
Drug: biguanide treatment
RxNorm normalized name: biguanide
DrugBank: Biguanide (DB13100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biguanide treatment
Trial: 23868188
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg with weekly paclitaxel 90 mg/m²
Trial: 23868188
Drug: Tivozanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib plus weekly paclitaxel
Trial: 21619503
Drug: Local infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infusion analgesia (LINFA) with Ropivacain, Ketorolac, and Adrenaline administered through a catheter
Trial: 21619503
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered through a catheter
Trial: 21619503
Drug: Local infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infusion analgesia (LINFA)
Trial: 21641354
Drug: Transendocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial injection of autologous bone marrow mononuclear cells (ABMMNCs)
Trial: 15364865
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ABMMNC injection)
Trial: 22964967
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg)
Trial: 8834129
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 to 10 mg/day)
Trial: 2390281
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (group A - 27 patients)
Trial: 7361799
Drug: 5th-grade level
RxNorm normalized name: Food Grade Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5th-grade level warfarin drug monograph
Trial: 7361799
Drug: 10th-grade level
RxNorm normalized name: Food Grade Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10th-grade level warfarin drug monograph
Trial: 21060031
Drug: Venlafaxine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (37.5 mg daily for 7 days followed by 75 mg daily for 21 days)
Trial: 21060031
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg once per day for 3 days, then 300 mg twice per day for 3 days, then 300 mg three times per day for 22 days)
Trial: 15859023
Drug: 7.5% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% NaCl infusion
Trial: 2791122
Drug: Gamma-neutron irradiation
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-neutron irradiation using 252Cf, physical dose 2 Gy
Trial: 31225839
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention consisting of four one‐on‐one sessions with a nurse interventionist during the patient's first, second, fourth, and sixth week of radiation treatment
Trial: 23880908
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (n=22)
Trial: 22910758
Drug: Intensive dose
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dose statin therapy
Trial: 19261367
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (verapamil and diltiazem)
Trial: 19261367
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (verapamil)
Trial: 19261367
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (diltiazem)
Trial: 15183850
Drug: 10% solution
RxNorm normalized name: Mucomyst 10% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% solution (v/v) of essential oil of Australian lemon myrtle (Backhousia citriodora)
Trial: 11773176
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (PCT) consisting of two cycles of mitomycin (6 mg/m(2), day 1), ifosfamide (1.5 g/m(2), days 1 to 3), and cisplatin (30 mg/m(2), days 1 to 3), plus two additional postoperative cycles for responding patients.
Trial: 30408319
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (PCT)
Trial: 2511687
Drug: Intravenous isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isosorbide dinitrate (mean dose 12.9 mg; range 7.7‐14.9)
Trial: 2511687
Drug: Buccal nitroglycerine
RxNorm normalized name: nitroglycerin Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal nitroglycerine (5 mg)
Trial: 2511687
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (nitro TTS 10)
Trial: 1066200
Drug: Zirconium silicate
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied every 6 months
Trial: 1066200
Drug: Zirconium silicate
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied once each year
Trial: 31248461
Drug: 12MP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12MP + Tet + TLR agonist without IFA (V0)
Trial: 31248461
Drug: 12MP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12MP + Tet + TLR agonist with IFA (V1)
Trial: 31248461
Drug: 12MP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12MP + Tet + TLR agonist with IFA (V6)
Trial: 31248461
Drug: Treatment-related dose-limiting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related dose-limiting toxicities (DLTs)
Trial: 12117049
Drug: TJ-96 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-96 (2.5 g orally 3 times daily for 4 weeks)
Trial: 23522721
Drug: NSAID therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID therapy (n=24)
Trial: 23522721
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (n=11)